Investor Omega Fund V, L.P.
13D/G Filings

This page shows a list of all the recent 13D/G filings made by Omega Fund V, L.P. . Schedule 13D is commonly referred to as a “beneficial ownership report.” The term "beneficial owner" is defined under SEC rules. It includes any person who directly or indirectly shares voting power or investment power (the power to sell the security).

When a person or group of persons acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities, they are required to file a Schedule 13D within ten days after the purchase. Click the link icon to see the full transaction history.

Add This Fund
to your dashboard

Date Form Target Prev
Shares		 Current
Shares		 Change
(Percent)		 Ownership
(Percent)		 Change
(Percent)
2024-11-14 13G/A KRON / Kronos Bio, Inc. 3,838,883 0
2024-10-18 13D/A NUVB / Nuvation Bio Inc. 15,072,340 13,072,340
2023-02-13 13G/A KRON / Kronos Bio, Inc. 3,818,283 3,838,883
2023-02-13 13D/A NUVB / Nuvation Bio Inc. 28,212,376 15,072,340
2022-02-14 13G/A CDTX / Cidara Therapeutics, Inc. 3,255,248 1,249,999
2022-02-14 13G/A MORF / Morphic Holding, Inc. 2,932,271 1,200,014
2021-02-19 13D NUVB / Nuvation Bio Inc. 28,212,376
2021-02-12 13G/A MORF / Morphic Holding, Inc. 2,969,582 2,932,271
2021-02-12 13G/A CDTX / Cidara Therapeutics, Inc. 2,890,513 3,255,248
2021-02-12 13G KRON / Kronos Bio, Inc. 3,818,283
2021-02-12 13G/A GOSS / Gossamer Bio, Inc. 6,119,345 3,320,608
2020-02-14 13G MORF / Morphic Holding, Inc. 2,969,582
2020-02-14 13G GOSS / Gossamer Bio, Inc. 6,119,345
2020-02-14 13G/A CDTX / Cidara Therapeutics, Inc. 1,508,794 2,890,513
2019-05-20 13D TRVI / Trevi Therapeutics, Inc. 1,263,230 1,263,230
2019-05-17 13D TRVI / Trevi Therapeutics, Inc. 1,263,230
2019-02-13 13G CDTX / Cidara Therapeutics, Inc. 1,508,794